[{"from": "human", "value": "Provide a brief overview of this molecule. [C][C][=C][C][=C][Branch2][Ring1][Ring2][N][=C][Branch1][Branch2][N][=C][Ring1][=Branch1][S][Ring1][=Branch2][N][C][C][N][C][C][Ring1][=Branch1][C][=C][C][=C][C][=C][Ring1][=Branch1][F].[O].[Cl]"}, {"from": "gpt", "value": "The molecule is both a noradrenaline reuptake inhibitor and a serotonin type 3 receptor (5-HT3) antagonist. Noradrenaline and serotonin are neurotransmitters that are known to be involved in the control of the gastrointestinal system.  The unique combination of noradrenaline reuptake inhibition and 5-HT3 antagonism in one orally delivered compound represents a novel approach to treating IBS-d and other functional GI diseases. Dynogen licensed preclinical and clinical data related to DDP225 from Mitsubishi Pharma in October 2003."}]